recurrent prostate cancer

December 3, 2020December 3, 2020

FDA Approves First PSMA-targeted PET Imaging Agent for Prostate Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) as a positron emission tomography or PET imaging agent for men with prostate cancer. The ... Read more

September 16, 2019

PSMA PET-CT Offers Better Detection Rates in Recurrent PC, Study Says

News

The imaging agent 68Ga-PSMA-11 has better detection rates than 18F-fluciclovine in men with recurrent prostate cancer who have already had radical surgery to remove the prostate and whose levels of ... Read more

July 8, 2019

68Ga-PSMA-11 Better than Axumin at Detecting PC Recurrence, Trial Shows

News

Among men suspected of having prostate cancer recurrence after surgery, the radiotracer 68Ga-PSMA-11 is better at detecting the cancerous lesions and provides better agreement among experts than the standard Axumin ... Read more

April 22, 2019

68Ga-PSMA-11 PET Scan Accurate, Safe in Detecting Recurrent PC, Study Says

News

68Ga-PSMA-11 PET scans are highly accurate, reproducible, and safe for detecting prostate cancer that has come back after prior therapy with prostate surgery or radiation therapy, a study shows. The ... Read more

June 21, 2018

Axumin PET/CT Scans Lead to Treatment Changes in Most Recurring Prostate Cancer Patients, Phase 3 Trial Shows

News

In men suspected of recurring prostate cancer, imaging with Axumin (18F-fluciclovine) was able to accurately reveal sites of recurrence, which led to a change of treatment plans for 59 percent of the ... Read more

October 2, 2017October 2, 2017

Axumin PET/CT Scans in Men with Suspected Recurrent Prostate Cancer May Change Treatment Plans

News

More than six out of 10 men whose doctors suspected their prostate cancer had returned due to rising prostate specific antigen (PSA) levels saw their treatment plans revised after being ... Read more

June 9, 2017

TYME-88 Seen to Stop Progression of Recurrent, Non-Metastatic Prostate Cancer in Early Trial Data

News

Preliminary results from a Phase 1b/2 clinical trial evaluating the safety, pharmacokinetics, and efficacy of TYME-88 (SM-88) to treat recurrent, non-metastatic prostate cancer found that all eight enrolled patients, who did not ... Read more

May 5, 2017May 5, 2017

Physicians Can Be Trained to Interpret Axumin PET Images of Recurrent Prostate Cancer, Study Finds

News

A study supported by Blue Earth Diagnostics showed that physicians can be trained to successfully interpret Axumin PET scan images of patients with suspected recurrence of prostate cancer. Axumin is ... Read more